Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  

































Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Medical uses  





2 History  



2.1  Timeline  







3 Society and culture  



3.1  Names  







4 See also  





5 References  














NPH insulin






العربية
Español
فارسی
Français

Հայերեն
Nederlands

ି
Português
Română
Русский
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Tiếng Vit

 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 
















Appearance
   

 






From Wikipedia, the free encyclopedia
 


NPH insulin
A vial of NPH insulin with insulin syringe
Clinical data
Trade namesNovolin N, Humulin N, Insulatard, others
Other namesNeutral protamine Hagedorn insulin,[1]
protamine zinc insulin (slightly different),[2]
isophane insulin,[2]
compound insulin zinc suspension (slightly different),[2]
intermediate-acting insulin
AHFS/Drugs.comMonograph
MedlinePlusa682611
Routes of
administration
Subcutaneous
ATC code
Legal status
Legal status
  • EU: Rx-only
  • Pharmacokinetic data
    Onset of action90 minutes[3]
    Duration of action24 hours[3]
    Identifiers
    CAS Number
    ChemSpider
    • none

    Neutral Protamine Hagedorn (NPH) insulin, also known as isophane insulin, is an intermediate-acting insulin given to help control blood sugar levels in people with diabetes.[3] It is used by injection under the skin once to twice a day.[1] Onset of effects is typically in 90 minutes and they last for 24 hours.[3] Versions are available that come premixed with a short-acting insulin, such as regular insulin.[2]

    The common side effect is low blood sugar.[3] Other side effects may include pain or skin changes at the sites of injection, low blood potassium, and allergic reactions.[3] Use during pregnancy is relatively safe for the fetus.[3] NPH insulin is made by mixing regular insulin and protamine in exact proportions with zinc and phenol such that a neutral-pH is maintained and crystals form.[1] There are human and pig insulin based versions.[1]

    Protamine insulin was first created in 1936 and NPH insulin in 1946.[1] It is on the World Health Organization's List of Essential Medicines.[4] NPH is an abbreviation for "neutral protamine Hagedorn".[1] In 2020, insulin isophane was the 221st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[5][6] In 2020, the combination of human insulin with insulin isophane was the 246th most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]

    Medical uses[edit]

    NPH insulin is cloudy and has an onset of 1–3 hours. Its peak is 6–8 hours and its duration is up to 24 hours.[9]

    It has an intermediate duration of action, meaning longer than that of regular and rapid-acting insulin, and shorter than long acting insulins (ultralente, glargineordetemir). A recent Cochrane systematic review[10] compared the effects of NPH insulin to other insulin analogues (insulin detemir, insulin glargine, insulin degludec) in both children and adults with Type 1 diabetes. Insulin detemir appeared provide a lower risk of severe hyperglycemia compared to NPH insulin, however this finding was inconsistent across included studies.[10] In the same review no other clinically significant differences were found between different insulin analogues in either adults nor children.[10]

    History[edit]

    Hans Christian Hagedorn (1888–1971) and August Krogh (1874–1949) obtained the rights for insulin from Frederick Banting and Charles BestinToronto, Canada. In 1923 they formed Nordisk Insulin laboratorium, and in 1926 with August Kongsted he obtained a Danish royal charter as a non-profit foundation.

    In 1936, Hagedorn and B. Norman Jensen discovered that the effects of injected insulin could be prolonged by the addition of protamine obtained from the "milt" or semen of river trout. The insulin would be added to the protamine, but the solution would have to be brought to pH 7 for injection. University of Toronto, Canada later licensed protamine zinc insulin (PZI),[11] to several manufacturers. This mixture only needs to be shaken before injection. The effects of PZI lasted for 24–36 h.

    In 1946, Nordisk was able to form crystals of protamine and insulin and marketed it in 1950, as neutral protamine Hagedorn (NPH) insulin. NPH insulin has the advantage that it can be mixed with an insulin that has a faster onset to complement its longer lasting action.[medical citation needed]

    Eventually all animal insulins made by Novo Nordisk were replaced by synthetic, recombinant 'human' insulin.[medical citation needed] Synthetic 'human' insulin is also complexed with protamine to form NPH.[medical citation needed]

    Timeline[edit]

    The timeline is as follows:[citation needed]

    Society and culture[edit]

    Names[edit]

    NPH stands for neutral protamine Hagedorn, and the words refer to neutral pH (pH = 7), protamine (a protein), and Hans Christian Hagedorn (an insulin researcher).Brand names include Humulin N, Novolin N, Novolin NPH, Gensulin N, SciLin N, Insulatard, and NPH Iletin II.[citation needed]

    See also[edit]

    References[edit]

    1. ^ a b c d e f Owens DR (1986). Human Insulin: Clinical Pharmacological Studies in Normal Man. Springer Science & Business Media. pp. 134–136. ISBN 9789400941618. Archived from the original on 2017-01-18.
  • ^ a b c d British national formulary: BNF 69 (69 ed.). British Medical Association. 2015. pp. 464–472. ISBN 9780857111562.
  • ^ a b c d e f g "Insulin Human". The American Society of Health-System Pharmacists. Archived from the original on 22 October 2016. Retrieved 8 January 2017.
  • ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  • ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  • ^ "InsulinIsophane - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  • ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  • ^ "Insulin Human; Insulin Isophane Human - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  • ^ "NPH insulin | DrugBank Online". go.drugbank.com. Retrieved 2022-09-09.
  • ^ a b c Hemmingsen B, Metzendorf MI, Richter B (March 2021). "(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus". The Cochrane Database of Systematic Reviews. 3 (3): CD013498. doi:10.1002/14651858.cd013498.pub2. PMC 8094220. PMID 33662147.
  • ^ "The History of Insulin" (PDF). Karger.com/. Basel, Switzerland: Karger Publishers. Archived from the original (PDF) on March 4, 2016. Retrieved June 10, 2015.

  • Retrieved from "https://en.wikipedia.org/w/index.php?title=NPH_insulin&oldid=1190944769"

    Categories: 
    Insulin receptor agonists
    Human proteins
    Recombinant proteins
    Peptide hormones
    Peptide therapeutics
    Drugs developed by Eli Lilly and Company
    World Health Organization essential medicines
    Medical mnemonics
    Hidden categories: 
    Articles with short description
    Short description is different from Wikidata
    Articles needing additional references from November 2020
    All articles needing additional references
    Drugs with non-standard legal status
    Chemicals that do not have a ChemSpider ID assigned
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without KEGG source
    Articles without InChI source
    Articles without UNII source
    Articles containing unverified chemical infoboxes
    All articles with unsourced statements
    Articles with unsourced statements from November 2020
    Articles with unsourced statements from May 2022
    Wikipedia medicine articles ready to translate
     



    This page was last edited on 20 December 2023, at 19:33 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki